Article Information
History
- January 31, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Karin Hardt, Ph.D.1,
- An Vandebosch, Ph.D.1,
- Jerry Sadoff, M.D.2,
- Mathieu Le Gars, Ph.D.2,
- Carla Truyers, Ph.D.1,
- David Lowson, M.Sc.3,
- Ilse Van Dromme, Ph.D.1,
- Johan Vingerhoets, Ph.D.1,
- Tobias Kamphuis, Ph.D.2,
- Gert Scheper, Ph.D.2,
- Javier Ruiz-Guiñazú, M.D.1,
- Saul N. Faust, F.R.C.P.C.H.4,
- Christoph D. Spinner, M.D.5,
- Hanneke Schuitemaker, Ph.D.2,
- Johan Van Hoof, M.D.2,
- Macaya Douoguih, M.D.2,
- Frank Struyf, M.D.1,*,
- the ENSEMBLE2 Study Group
- 1Janssen Research and Development, Beerse, Belgium
- 2Janssen Vaccines and Prevention, Leiden, The Netherlands
- 3Janssen Research and Development, High Wycombe, UK
- 4NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK
- 5Technical University of Munich, Munich, Germany
- ↵*Corresponding Author:
Frank Struyf, M.D.; Email: FStruyf{at}ITS.JNJ.com